Predictors of Virological Failure Among People Living with HIV Switching from an Effective First-Line Antiretroviral Regimen.


Journal

AIDS research and human retroviruses
ISSN: 1931-8405
Titre abrégé: AIDS Res Hum Retroviruses
Pays: United States
ID NLM: 8709376

Informations de publication

Date de publication:
06 2022
Historique:
pubmed: 1 1 2022
medline: 10 6 2022
entrez: 31 12 2021
Statut: ppublish

Résumé

Aim of this study was to assess the predictors of virological failure (VF) among patients living with HIV (PLWHIV) switching from an effective first-line antiretroviral therapy (ART) regimen, and to evaluate the emergence of resistance-associated mutations. All adult patients enrolled in the Antiviral Response Cohort Analysis cohort who started ART after 2010, with at least 6 months of virological suppression (VS) before ART switch and with an available genotypic resistance test (GRT) at baseline were included. Thirty-two patients out of the 607 PLWHIV included (5.3%) experienced VF after a median of 11 months from ART switch. Younger age (adjusted Hazard Ratio [aHR] 0.96, 95% confidence interval [CI] 0.92-0.99,

Identifiants

pubmed: 34969260
doi: 10.1089/AID.2021.0016
doi:

Substances chimiques

Anti-HIV Agents 0
Anti-Retroviral Agents 0
Protease Inhibitors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

463-471

Auteurs

Laura Magnasco (L)

Infectious Diseases Unit, Ospedale Policlinico San Martino - IRCCS per l'Oncologia, Genoa, Italy.

Rachele Pincino (R)

Infectious Diseases Unit, Ospedale Policlinico San Martino - IRCCS per l'Oncologia, Genoa, Italy.
Department of Health's Sciences, University of Genoa, Genoa, Italy.

Giuseppe Pasculli (G)

Department of Computer, Control, and Management Engineering Antonio Ruberti (DIAG), La Sapienza University, Rome, Italy.

Yagai Bouba (Y)

Department of Experimental Medicine, University of Rome "Tor Vergata," Rome, Italy.
Chantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB), Yaoundé, Cameroon.

Francesco Saladini (F)

Department of Medical Biotechnologies, University of Siena, Siena, Italy.

Davide Fiore Bavaro (DF)

Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari "Aldo Moro," Bari, Italy.

Andrea De Vito (A)

Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.

Rossana Lattanzio (R)

Department of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari "Aldo Moro," Bari, Italy.

Romina Corsini (R)

Infectious Diseases Unit, AUSL - IRCCS Reggio Emilia, Reggio Emilia, Italy.

Maurizio Zazzi (M)

Department of Medical Biotechnologies, University of Siena, Siena, Italy.

Francesca Incardona (F)

InformaPRO s.r.l., Rome, Italy - EuResist Network GEIE, Rome, Italy.

Barbara Rossetti (B)

Infectious Diseases Unit, Azienda Ospedaliero-Universitaria Senese, Siena, Italy.

Antonia Bezenchek (A)

InformaPRO s.r.l., Rome, Italy - EuResist Network GEIE, Rome, Italy.

Vanni Borghi (V)

Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy.

Antonio Di Biagio (A)

Infectious Diseases Unit, Ospedale Policlinico San Martino - IRCCS per l'Oncologia, Genoa, Italy.
Department of Health's Sciences, University of Genoa, Genoa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH